Biopharmaceutical companies Gilead (NASDAQ: GILD) and Arcus Biosciences (NYSE: RCUS) have announced safety and efficacy data from a Phase Ib/II clinical trial for a combination therapy in third-line metastatic colorectal cancer (mCRC). The trial evaluated the combination of adenosine receptor antagonist etrumadenant, anti-PD-1 drug zimberelimab, VEGF inhibitor bevacizumab, and chemotherapy against the monotherapy of kinase inhibitor regorafenib.
The results showed that the combination therapy significantly increased overall survival (OS) from 9.5 to 19.7 months and improved progression-free survival (PFS) from 2.1 to 6.2 months compared to regorafenib. Moreover, the rate of adverse events was lower for the candidate treatment combination than for regorafenib alone, presenting a safety profile in line with each of its individual components.- Flcube.com
